TipRanks
Advertisement
Advertisement

CH:BSLN Stock Latest News

Basilea price target raised to CHF 110 from CHF 105 at H.C. Wainwright
The FlyBasilea price target raised to CHF 110 from CHF 105 at H.C. Wainwright
28d ago
Basilea Pharmaceutica Earnings Call Signals Confident Growth
PremiumCompany Announcements
Basilea Pharmaceutica Earnings Call Signals Confident Growth
2M ago
Basilea lifts 2026 profit outlook as anti-infectives pipeline and Cresemba sales power H1 results
PremiumCompany Announcements
Basilea lifts 2026 profit outlook as anti-infectives pipeline and Cresemba sales power H1 results
2M ago
Basilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs
PremiumCompany Announcements
Basilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs
2M ago
BARDA injects $30 million into Basilea’s phase 3 antifungal program
PremiumCompany Announcements
BARDA injects $30 million into Basilea’s phase 3 antifungal program
2M ago
PremiumCompany AnnouncementsBasilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs
4M ago
Premium
Company Announcements
Basilea Wins CARB-X Funding Boost for First-in-Human Trial of Novel Antibiotic BAL2420
6M ago
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
Premium
Company Announcements
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
8M ago
Basilea Pharmaceutica Earnings Call Highlights Pipeline Push
PremiumCompany Announcements
Basilea Pharmaceutica Earnings Call Highlights Pipeline Push
8M ago
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
PremiumCompany Announcements
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
8M ago
Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
PremiumCompany Announcements
Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
10M ago
BSLN
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
PremiumRatings
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
10M ago
Basilea Achieves Sales Milestone with Cresemba in Europe
PremiumCompany AnnouncementsBasilea Achieves Sales Milestone with Cresemba in Europe
11M ago
Basilea Secures BARDA Funding for Novel Antibiotic Development
Premium
Company Announcements
Basilea Secures BARDA Funding for Novel Antibiotic Development
1y ago
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
Premium
Ratings
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
1y ago
Basilea Secures Additional BARDA Funding for Antifungal Development
PremiumCompany Announcements
Basilea Secures Additional BARDA Funding for Antifungal Development
1y ago
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
PremiumCompany Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
1y ago
BSLN
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
1y ago
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
1y ago
BSLN
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
PremiumCompany AnnouncementsBasilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
1y ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
1y ago
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
Premium
Company Announcements
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >